ms & mogad: differences in response to immunomodulatory therapies
Published 1 year ago • 707 plays • Length 2:01Download video MP4
Download video MP3
Similar videos
-
1:49
the pathology of ms and mogad: similarities and differences
-
1:23
research developments in mogad
-
48:36
913. avoiding a misdiagnosis: understanding the differences between mogad, ms, and nmosd
-
1:10:50
overlaps & differences between mogad, ms & nmosd
-
1:17
predicting relapses in mogad
-
2:55
the immune mechanisms behind neurodegeneration in progressive ms
-
3:04
predictive and prognostic biomarkers for pediatric mogad and nmosd
-
28:00
2021 rnds | mog antibody disease (mogad)
-
2:21
meteoroid: phase iii trial of satralizumab in patients with mogad
-
1:04
should routine mri surveillance be implemented in nmosd and mogad?
-
1:56
the impact of comorbidities on treatment-related decisions in ms
-
1:54
controversies in treating nmosd and mogad
-
51:11
205. mogad and nmosd: is mogad part of nmosd or a distinct diagnosis?
-
23:37
2018 rnds — mog antibody-associated disease
-
13:27
myelin oligodendrocyte glycoprotein antibody-associated disease (mogad)
-
54:07
808. mog antibody disease: adult and pediatric presentations
-
14:17
2020 rnds | what is mog antibody disease (mogad)?
-
43:07
2021 rnds | how do you get a diagnosis of adem, afm, mogad, nmosd, on, and tm?
-
55:39
912. mog antibody disease: diagnosis and treatment guidelines